browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
aa36523c-671a-47b0-964e-cd6d85cbcecf
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 16:14:54
Income (reported)
$50,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

CROSSROADS STRATEGIES, LLC

lobbying firm

Contact
MATHEW LAPINSKI
Phone
+1 202-559-0170
Address
zip:20002, city:Washington, state:DC, street:800 North Capitol Street, NW, Suite 800
Client

HALEON US HOLDINGS LLC

consumer health care company

State
NJ
Country
US
Effective date
2024-01-01
Issues lobbied + lobbyists (5)

BUD — Budget/Appropriations

Policies impacting access to over-the-counter products; FY2026 Financial Services and General Government Appropriations Act process (H.R.5166/S.3290); H.R.7148, Making further consolidated appropriations for the fiscal year ending September 30, 2026, and for other purposes (P.L.119-75).

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

TRD — Trade (domestic/foreign)

Policies impacting the supply chain and manufacturing of over-the-counter pharmaceutical products including tariffs.

Lobbyists:

Government entities lobbied: Bureau of Industry and Security (BIS); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Issues related to healthcare and payment for over-the-counter drugs; General education of over-the-counter switches, including reauthorization of the Over-the-Counter Monograph Drug User Fee Act and policies impacting a Nonprescription Drug Product with an Additional Condition for Nonprescription Use.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.